Flexible Work
AARP Skills Builder
Flexible Work
ON-DEMAND WEBINARS
Drug Prices
Social Security
Medicare & Medicaid
Caregiving
LONG-TERM CARE
State Guides
Prepare to Care Guides
End of Life
Home Technology
Get Happier
POSSIBILITIES OF AI
Relationships
Home Health
Leaving AARP.org Website
You are now leaving AARP.org and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.
BrandAmp by AARP provides the opportunity for our highly vetted marketing partners to share their expert knowledge, insights and storytelling with loyal and engaged readers like you. Each piece of paid content is created in collaboration with the disclosed advertiser and AARP Media Sales’ content development team.
BrandAmp by AARP content is designed to uphold AARP standards of excellence and inspire conversation. Only advertisers who have gone through the strictest reviews are cleared to bring their message directly to members using all of AARP media properties (AARP.org, social media, email newsletters and our print publications). Our pledge to members is work with brands whose products and services are of value to the 50+ audience; and are committed to the type of compelling, informative, entertaining and useful content members are accustomed to seeing within AARP media properties.
You are now leaving AARP.org and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.
Medicare will begin nationwide coverage of CAR T-cell therapy, a complicated treatment for some cancer patients who have run out of other treatment options, the Centers for Medicare and Medicaid Services (CMS) announced on Wednesday.
The Food and Drug Administration has approved chimeric antigen receptor T-cell, or CAR T-cell, therapy to treat some specific cancers, including certain types of non-Hodgkin’s lymphoma. The treatment involves removing some of the patient’s own CAR T-cells, genetically modifying them, and then putting them back into the patient so they can attack a protein on the surface of cancer cells. The treatment — which is applied once — is estimated to cost between $375,000 and $475,000.
“Today’s coverage decision provides consistent and predictable patient access nationwide,” CMS Administrator Seema Verma said in a statement. “CMS will work closely with our sister agencies to monitor outcomes for Medicare patients receiving this innovative therapy going forward.”
Medicare said it will cover CAR T-cell therapy when it is performed in facilities enrolled in an FDA safety program that includes training in handling side effects of such treatments.
“We’ve recently seen dramatic progress in the development of CAR T-cell therapies and other treatments that harness patients’ own immune cells to treat their cancers, and we continue to learn more in clinical studies,” says Douglas R. Lowy, acting director of the National Cancer Institute, where the first successful cancer treatment with CAR T-cells was developed. “By partnering with CMS and FDA, we have an opportunity to increase our understanding of how different patients’ cancers respond to these treatments through the collection of this data, ultimately allowing us to better understand who will benefit from these therapies.”
More on Health and Medicare
A Sea Change in Lung Cancer Treatment
New study shows lifesaving results with immunotherapy drug
Understanding Medicare's Plans and Costs
Medicare's role in simplifying health care costs